{"entity":{"id":"nct05467748","kind":"trial","name":"EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of tulmimetostat with PD-1 blockade in advanced non-small-cell lung cancer, run by VA Office of Research and Development, now recruiting.","summary":"EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05467748 by VA Office of Research and Development, with VA Greater Los Angeles Healthcare System as collaborator; 66 participants are planned, it started on 2025-12-08; the registry gives 2027-12-08 as its primary completion date. Interventions recorded: Tulmimetostat. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05467748","url":"https://clinicaltrials.gov/study/NCT05467748"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tulmimetostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05467748","phase":"1/2","setting":"Phase Ib/II Study of Safety and Efficacy of EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer","sponsor":"VA Office of Research and Development","started":"2025-12-08","enrolled":66,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05467748/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"tulmimetostat","kind":"drug","name":"Tulmimetostat","route":"/drugs/tulmimetostat/"}]}}